The sequence of the gyrase B subunit gene from Staphylococcus aureus strains resistant to the gyrase B subunit inhibitors cyclothialidine, coumermycin, and novobiocin has been determined. The residues altered in the resistant gyrase B subunits map to the ATP-binding region, suggesting that the drugs inhibit ATP binding and hydrolysis. The pattern of cross-resistances indicates that the detailed binding mode of the compounds differs.
thialidines, the compound Ro 47-5990 ( Fig. 1 ) was used for the selection because it has a very good in vitro activity. Genomic DNA was isolated from drug-resistant strains, and the gyrase B subunit gene was amplified by the PCR from 1 g of genomic DNA, using the primers P1 (5ЈcagaaagcCatggtgactgcattg3Ј, nucleotides 273 to 296 in the sequence published by Brockbank and Barth [3] ) and P2 (5ЈcagttcacaAAgcttagaag3Ј, nucleotides 2229 to 2210 in the sequence published by Brockbank and Barth [3] ), as outlined by Ausubel et al. (2) . The bases shown in uppercase letters introduce a NcoI site in P1 and a HindIII site in P2. These sites were used to clone the PCR fragments into E. coli expression vectors (data not shown). The PCR fragments were purified and directly sequenced without subcloning. The complete B subunit gene was sequenced from the wild-type strain as well as from S. aureus strains with decreased susceptibility to cyclothialidines. From the coumarin-resistant S. aureus strains, an amino-terminal fragment of the B subunit gene, defined by primers P1 and P3 (5ЈctgtgaagCtttctccatctg3Ј, nucleotides 837 to 817 in the sequence published by Brockbank and Barth [3] ; the base shown in an uppercase letter introduces a HindIII site), which encodes the ATP-binding domain of the B subunit, was sequenced.
We determined that the sequence of the wild-type gyrase B gene from S. aureus is very similar to the sequence published by Brockbank and Barth (3) . We find the following nine single base changes, compared with the sequence of Brockbank and Barth (3): A at position 1034 (A-1034) to G, T-1169 to C, A-1232 to C, T-1487 to A, A-1574 to T, T-1598 to C, A-1679 to G, T-1748 to C, and T-2084 to C. Of these, eight differences are silent base changes. The only amino acid difference is a replacement of the glutamic acid residue at position 317 in the sequence of Brockbank and Barth by an aspartic acid residue in our sequence. In agreement with Brockbank and Barth, we find many discrepancies relative to the sequence reported by Margerrison et al. (19) . Our sequence differences relative to the sequence reported by Brockbank and Barth are probably due to strain-to-strain variabilities in the sequence of the gyrase B subunit gene.
The mutations found in the gyrase B genes from drug-resistant strains are shown in Table 1 . The MICs of the different drugs for these strains are summarized in Table 2 . To exclude the possibility that resistance to the B subunit inhibitors is due to a general efflux mechanism, we have tested the susceptibility of each strain to ciprofloxacin, tetracycline, and erythromycin. There was no difference in susceptibility towards these drugs (data not shown). All of the mutations reported here were found in more than one isolate. For reasons of clarity, only one isolate with each type of mutation is shown in Table 2 . Single mutations confer a 32-to 64-fold decreased susceptibility to novobiocin (a Gly-to-Ser mutation at position 85 [Gly85-Ser], Ile102-Ser, and Arg144-Ile). These novobiocin-resistant isolates are also less susceptible to different levels of coumermycin (8-to 256-fold increase in MIC compared with the wild type). Strains resistant to even higher levels of coumermycin had two amino acid changes (Arg144-Ile and Ile175-Thr). The arginine at position 136 of E. coli gyrase B has been demonstrated to confer coumarin resistance to E. coli (4, 6) . This residue is analogous in position to the arginine 144 of S. aureus gyrase B. In Streptococcus pneumoniae, a Ser127-Leu (equivalent to Ser-128 in S. aureus) substitution is implicated in novobiocin resistance (21) . Three novobiocin-resistant strains of the halophilic archaebacterium Haloferax have been reported (12) . The gyrase B residues mutated in these isolates are Asp89-Gly, Ser129-Thr, and Arg144-His (numbered as in S. aureus gyrase B). Our results indicate that it is not absolutely necessary to mutate Arg-144 of gyrase B to decrease the susceptibility to coumarins. Mutations of Gly-85 and Ile-102 of gyrase B also give strains which are inhibited less efficiently than wild-type S. aureus by the coumarins.
Of the coumarin-resistant S. aureus strains, only the one with the gyrase B mutation in position 102 requires an increased MIC of the cyclothialidines Ro 47-5990 and Ro 48-2865 (Fig.  1) . In the isolates resistant to higher levels of these cyclothialidines, two amino acid changes in the S. aureus gyrase B gene (Ala108-Ser and Ser128-Leu or Ile102-Val and Thr173-Asn) were found. While the Ala108-Ser, Ser128-Leu mutant is highly resistant to novobiocin, it exhibits a susceptibility to coumermycin almost equal to that of the wild type. The Ile102-Val, Thr173-Asn mutant is highly resistant to both novobiocin and coumermycin. It is possible that mutations in the gyrase B gene are not sufficient to obtain resistance to gyrase B inhibitors, but the fact that we found all mutations in more than one strain indicates that they are necessary for resistance. Attempts to demonstrate resistance with purified recombinant gyrase B subunits from resistant strains have failed, because of the largely reduced activity of mutant enzymes in an in vitro supercoiling assay (data not shown).
Our results clearly suggest that all three antibiotics bind close to the ATP-binding site of S. aureus gyrase B. Because the ATPase activity of mutant gyrase B subunits still has to be sufficient to support the supercoiling activity of DNA gyrase, only amino acids not directly involved in ATP binding are mutated in the drug-resistant isolates. Nevertheless, it has been reported that coumarin-resistant DNA gyrase B subunits from E. coli have a reduced ATPase activity (1, 4) .
The complex pattern of cross-resistances observed indicates that the cyclothialidines and the coumarins make contacts with overlapping regions of the gyrase B subunit but that the type of interactions is not exactly identical in these two cases. Cyclothialidines and coumermycin seem to make more contacts with the gyrase B subunit than novobiocin, since single mutations can confer resistance to high concentrations of novobiocin while double mutations are associated with a strongly decreased susceptibility to cyclothialidines and coumermycin. This could be caused by the bulkier molecular nature of coumermycin and cyclothialidine compared with novobiocin.
For a more detailed analysis of the binding mode of B subunit inhibitors, the X-ray structure of inhibitor B subunit complexes is eagerly awaited. The crystallization of an N-terminal 24-kDa fragment of the DNA gyrase B protein complexed with novobiocin and GR122222X, a compound structurally related to cyclothialidine, has recently been reported, but so far no X-ray structures of these complexes have been published (18) . 
